Voreloxin Gets Orphan Drug Status for Acute Myeloid Leukemia

News
Article
OncologyONCOLOGY Vol 23 No 14
Volume 23
Issue 14

Sunesis Pharmaceuticals, Inc, announced that the US Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two phase II clinical trials of voreloxin in AML: a single-agent study (REVEAL-1) in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating the drug in combination with cytarabine in relapsed/refractory AML.

Sunesis Pharmaceuticals, Inc, announced that the US Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two phase II clinical trials of voreloxin in AML: a single-agent study (REVEAL-1) in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating the drug in combination with cytarabine in relapsed/refractory AML.

Voreloxin is a first-in-class anticancer quinolone derivative, a class of compounds that has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, G2 arrest, and apoptosis.

Articles in this issue
CYP2D6 Testing in Breast Cancer: Ready for Prime Time?
Tamoxifen, Endoxifen, and CYP2D6: The Rules for Evaluating a Predictive Factor
CYP2D6 Testing for Breast Cancer Patients: Is There More to the Story?
Adult T-cell Leukemia/ Lymphoma: Complexities in Diagnosis and Novel Treatment Strategies
Adjuvant Treatment After Orthotopic Liver Transplantation: Is It Really Necessary?
Recurrent Urothelial Carcinoma With Pulmonary Metastasis
Hepatocellular Carcinoma: The Search for Innovative Adjuvant Therapies
Getting a Handle on Posttransplant Recurrence of HCC
Survivin(g) Adult T-cell Leukemia/Lymphoma
Mediterranean Diet
Mediterranean Diet
Innovative Strategies Improve Outcomes and Reduce Complications Associated With Stem Cell Transplants
Advances in Optimizing Therapy and Quality of Life for People With Hard-to-Treat Blood Cancers
Advances in Genetics and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders
Major Cancer Agencies Respond to USPSTF’s New Mammography Guidelines
CMS Releases 2010 Physician Fee Schedule
Recent Videos
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A phase 1/2 trial assessed the use of menin inhibitor DSP-5336 in patients with acute leukemia overexpressing HOXA9 and MEIS1.
Related Content
The updated labeling also includes new information on the recommended dosage of fludarabine phosphate when given with cyclophosphamide and rituximab.

FDA Updates Fludarabine Phosphate Labeling in Chronic Lymphocytic Leukemia

Russ Conroy
November 21st 2024
Article

The updated labeling also includes new information on the recommended dosage of fludarabine phosphate when given with cyclophosphamide and rituximab.

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Elizabeth Shpall, MD
May 29th 2019
Podcast

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

Optimal Sequencing Between CAR T and Bispecifics in Multiple Myeloma

Optimal Sequencing Between CAR T and Bispecifics in Multiple Myeloma

ONCOLOGY Staff
November 20th 2024
Article

The use of CAR T-cell therapy and other sequencing options were discussed for patients with multiple myeloma.

Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

David T. Scadden, MD
March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.

Using Real-World Data to Form GPRC5D Therapy Strategies in R/R Multiple Myeloma

Using Real-World Data to Form GPRC5D Therapy Strategies in R/R Multiple Myeloma

ONCOLOGY Staff
November 18th 2024
Article

Experts in multiple myeloma discussed real-world efficacy and safety data associated with the use of GPRC5D-targeting bispecific agents to treat patients with R/R multiple myeloma.

BTK Inhibitor Treatment Options Across the Lymphoma Landscape

BTK Inhibitor Treatment Options Across the Lymphoma Landscape

ONCOLOGY Staff
November 17th 2024
Article

Clinicians focused on CLL, follicular lymphoma, and MCL gathered during a Frontline Forum to discuss the use of BTKi in each respective disease state.